Schedule 13D ownership disclosure

ENTASIS THERAPEUTICS HLDGS I

Security class unavailable · CUSIP: 293614103

Event date: 2022-01-12

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,020,748
Percent of class
2.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-22-000434
Form type
SC 13D/A
Filer
Entasis Therapeutics Holdings Inc.
CIK
CIK 1724344
Filed
Jan 18, 2022
Reporting period
Jan 12, 2022
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub